Power of The Dream Ventures (PWRV) 10-Q 13 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Oct. 14, 2015
Document And Entity Information
Entity Registrant Name	Power of The Dream Ventures Inc
Entity Central Index Key	1,377,888
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		46,700,896
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current Assets
Cash	$ 1,021	$ 1,524
Other receivables	60,441	81,048
Inventories	17,507	18,825
Total Current Assets	78,969	101,397
Intangibles	286,151	315,327
Fixed assets, net	66,245	92,043
Total Assets	431,365	508,767
Current Liabilities
Accounts payable and accrued and other liabilities	4,946,447	4,465,149
Grants received	(1,088,581)	(1,170,492)
Capital leases payable, current portion	44,070	50,622
Short term loans from related parties	85,866	144,045
Liability from warrants	11,932	63,638
Note payable	330,964	330,964
Short term loans	2,300,929	2,304,120
Total Current Liabilities	8,808,789	8,529,030
Stockholders' Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized,5,990,000 and 5,920,000 issued of which Series "A", of which Series "B", of which Series "C", of which Series "D", of which Series "E"	5,990	5,920
Common stock, $.001 par value;100,000,000 shares authorized, 47,900,896 and 46,700,896 shares issued and outstanding	47,901	46,701
Additional Paid-In Capital	36,335,444	36,246,114
Deficit accumulated during development stage	(45,433,292)	(44,854,780)
Other Comprehensive Income	666,533	535,782
Total Stockholders' Equity	(8,377,424)	(8,020,263)
Total liabilities and stockholders' equity	431,365	508,767
Series A Preferred Stock [Member]
Stockholders' Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized,5,990,000 and 5,920,000 issued of which Series "A", of which Series "B", of which Series "C", of which Series "D", of which Series "E"	2,000	2,000
Total Stockholders' Equity	2,000	2,000
Total liabilities and stockholders' equity	2,000	2,000
Series B Preferred Stock [Member]
Stockholders' Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized,5,990,000 and 5,920,000 issued of which Series "A", of which Series "B", of which Series "C", of which Series "D", of which Series "E"	1,000	1,000
Total Stockholders' Equity	1,000	1,000
Total liabilities and stockholders' equity	1,000	1,000
Series C Preferred Stock [Member]
Stockholders' Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized,5,990,000 and 5,920,000 issued of which Series "A", of which Series "B", of which Series "C", of which Series "D", of which Series "E"	1,000	1,000
Total Stockholders' Equity	1,000	1,000
Total liabilities and stockholders' equity	1,000	1,000
Series D Preferred Stock [Member]
Stockholders' Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized,5,990,000 and 5,920,000 issued of which Series "A", of which Series "B", of which Series "C", of which Series "D", of which Series "E"	1,000	1,000
Total Stockholders' Equity	1,000	1,000
Total liabilities and stockholders' equity	1,000	1,000
Series E Preferred Stock [Member]
Stockholders' Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized,5,990,000 and 5,920,000 issued of which Series "A", of which Series "B", of which Series "C", of which Series "D", of which Series "E"	990	920
Total Stockholders' Equity	990	920
Total liabilities and stockholders' equity	$ 990	$ 920

Consolidated Balance Sheet (Par

Consolidated Balance Sheet (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	5,990,000	5,920,000
Common stock, par value per share	$ .001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	47,900,896	46,700,896
Common stock, shares outstanding	47,900,896	46,700,896

Consolidated Statement Of Opera

Consolidated Statement Of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net Sales
Cost of Sales
Gross margin
Material expenses	$ 1,024	$ 5,444	$ 16,767	$ 23,892
General administration	$ 8,203	$ 320,912	$ 171,007	$ 716,524
Research and development
Personnel expenses	$ 5,048	$ 19,023	$ 24,842	$ 63,436
Depreciation and amortization	$ 14,099	20,338	$ 46,888	76,771
Grants received		(5,697)		29,162
Other expenses, net	$ 3,978	(109,039)	$ 16,156	(128,877)
Operating expenses	24,396	480,453	243,348	980,338
Profit (Loss) from operations	(24,396)	(480,453)	(243,348)	(980,338)
Interest expense and exchange differences	125,051	121,370	335,164	367,381
Profit (Loss) before income taxes	$ (149,447)	$ (601,823)	$ (578,512)	$ (1,347,719)
Income taxes
Net profit (loss)	$ (149,447)	$ (601,823)	$ (578,512)	$ (1,347,719)
Other comprehensive income	(28,130)	161,682	130,751	275,218
Total comprehensive income	$ (177,577)	$ (440,141)	$ (447,761)	$ (1,072,501)
Basic loss per share	$ 0	$ (0.01)	$ 0	$ (0.02)
Diluted loss per share	$ 0	$ (0.01)	$ 0	$ (0.02)
Weighted average number of shares outstanding - Basic	47,900,896	45,500,896	47,597,599	46,500,896
Weighted average number of shares outstanding - Diluted	47,900,896	45,500,896	47,597,599	46,500,896

Consolidated Statement Of Stock

Consolidated Statement Of Stockholders' Equity And Comprehensive Loss - 9 months ended Sep. 30, 2015 - USD ($)	Preferred Shares [Member]	Common Shares [Member]	Accumulated Deficit During Developmental Stage [Member]	Additional Paid In Capital [Member]	Other Comprehensive Income [Member]	Total
Balance preferred stock, shares at Dec. 31, 2014	5,920,000
Balance common stock, shares at Dec. 31, 2014		46,700,896				46,700,896
Balance, value at Dec. 31, 2014		$ 52,621	$ (44,854,780)	$ 36,246,114	$ 535,782	$ (8,020,263)
Debt conversion, shares		200,000
Debt conversion, value		$ 200		800		1,000
Private placement, shares	70,000
Private placement, value	$ 70			49,930		50,000
Issue for services, shares		1,000,000
Issue for services, value		$ 1,000		$ 38,600		39,600
Currency Translation Adjustment					$ 130,751	130,751
Net loss for the period			$ (578,512)			$ (578,512)
Balance preferred stock, shares at Sep. 30, 2015	5,990,000
Balance common stock, shares at Sep. 30, 2015		47,900,896				47,900,896
Balance, value at Sep. 30, 2015		$ 53,891	$ (45,433,292)	$ 36,335,444	$ 666,533	$ (8,377,424)

Consolidated Statement Of Cash

Consolidated Statement Of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net profit (loss)	$ (578,512)	$ (1,347,719)
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment of intangibles
Issue of shares for services	$ 39,600
Issue of shares for research and development
Change in value of liability from warrant	$ (51,706)	$ 80,741
Reversal of grant accrual
Depreciation and amortization	$ 46,888	$ 76,771
Total adjustments to reconcile net income loss to cash provided by operating activities before changes in operating assets and liabilities	(543,730)	(1,190,207)
Changes in operating assets and liabilities:
(Increase) Decrease in other current assets	(21,925)	(52,455)
(Decrease) Increase in accounts payable and accrued liabilities	398,730	165,128
Net cash used in operating activities	$ (123,075)	$ (972,624)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of fixed assets
Purchase of fixed assets
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from stockholders
Proceeds from sale of preferred stock	$ 50,000	$ 677,949
Proceeds from sale of common stock
Proceeds from related party loans	$ 58,179	$ 59,178
Proceeds from issuance of notes		154,000
Net cash from financing activities	$ (8,179)	772,771
Effect of exchange rate changes on cash	130,751	275,218
Net (decrease) increase in cash	(503)	75,365
Cash at beginning of period	1,524	22,922
Cash at end of period	1,021	$ 98,287
Non-cash investing and financing transactions
Issuance of shares for services	$ 39,600
Issuance of shares for liabilities assumed under reverse merger
Issuance of stock based compensation shares
Purchase of fixed assets through the assumption of capital lease obligations
Cash paid for: Interest
Cash paid for: Taxes

General Information

General Information	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General Information	NOTE 1 - GENERAL INFORMATION Power of the Dream Ventures, Inc., f/k/a “Tia V, Inc.” (“PDV” or the “Company”) was incorporated in Delaware on August 17, 2006, with the objective to acquire, or merge with, an operating business. Reverse merger PDV entered into and consummated a Securities Exchange Agreement (“Exchange Agreement”) on April 10, 2007. Under the terms of the Exchange Agreement, PDV acquired all the outstanding equity interests of Vidatech, Kft. (also known as Vidatech Technological Research and Development LLC) a limited liability company formed under the laws of the Republic of Hungary, (“Vidatech”) in exchange for 33,300,000 shares of PDV’s common stock, and Vidatech thereby became a wholly-owned Hungarian subsidiary of PDV. PDV is governed by the law of the State of Delaware, and its wholly-owned subsidiary, Vidatech, is governed by the law of the Republic of Hungary. PDV and Vidatech are herein collectively referred to as the “Company.” Following the acquisition the former stockholders of Vidatech owned a majority of the issued and outstanding common stock of PDV and the management of Vidatech controlled the Board of Directors of PDV and its wholly-owned Hungarian subsidiary Vidatech. Therefore the acquisition has been accounted for as a reverse merger (the “Reverse Merger”) with Vidatech as the accounting acquirer of PDV. The accompanying consolidated financial statements of the Company reflect the historical results of Vidatech, and the consolidated results of operations of PDV subsequent to the acquisition date. In connection with the Exchange Agreement, PDV adopted the fiscal year end of Vidatech as December 31. All reference to shares and per share amounts in the accompanying consolidated financial statements have been restated to reflect the aforementioned shares exchange. Business The Company is engaged in the acquisition, development, licensing and commercialization of and the investment in, directly or through business acquisitions, technologies developed in Hungary. In furtherance of its business, the Company provides research and development services to the companies, inventors from whom it acquires technologies or participation interests in technologies. A goal of the Company is to support research and development activities and to sell the products of inventions to the technological market. Basis of presentation The accompanying consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America for financial information have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading as of and for the period ended September 30, 2015. Going Concern and Management’s Plan The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate the continuation of the Company as a going concern and assume realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses from operations since inception. Management anticipates incurring additional losses in 2015. Further, the Company may incur additional losses thereafter, depending on its ability to generate revenues from the licensing or sale of its technologies and products, or to enter into any or a sufficient number of joint ventures. The Company has minimal revenue to date. There is no assurance that the Company can successfully commercialize any of its technologies and products and realize any revenues therefore. The Company’s technologies and products have never been utilized on a large-scale commercial basis and there is no assurance that any of its technologies or products will receive market acceptance. There is no assurance that the Company can continue to identify and acquire new technologies. As of September 30, 2015, the Company had an accumulated deficit of $45,433,292 and negative working capital of $(8,377,424). These circumstances raise substantial doubt about the ability of the company to continue as a going concern. During 2015 the Company raised a total of $50,000 through private placements of preferred stock. During 2014 and 2013 the Company raised a total of $677,949 and $401,500, respectively through private placements of common and preferred stock. These funds were used to finance operations, to reduce Genetic Immunity debt, and to finance Genetic Immunity’s regulatory process towards a marketing approval application. Additional funds used for these tasks, in the amount of $337,657 were previously provided in the prior years by the director, Peter Boros, who elected in November of 2013 to convert said loan into 1,000,000 shares of our Series D Preferred Stock. On December 31, 2014 the Company entered into a Promissory Note with a private person provided $22,964, in loans to the Company. The note bears interest at 10%, is due in one year. On July 28, 2014, on August 4, 2014, and on 14 August, 2014 the Company entered into three Promissory Notes with a private person provided $24,000, $55,000 and $75,000 dollars, respectively, in loans to the Company. The note bears interest at 10%, is due in one year. While the company has had limited success in raising funds to continue operating, it has significant debt and other liabilitiess due with in the next 12 months with no resources available and no specific plans in place to satisfy these liabilities. If the note holders and vendors demand payment when these liabilities come due, we will be unable to meet their demands and will likely be forced to liquidate. These consolidated financial statements do not include any adjustments relating to the recoverability of recorded asset amounts that might be necessary as a result of the above uncertainty.

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies adopted in preparation of the consolidated financial statements are set out below. Principles of Consolidation The consolidated financial statements include the accounts of PDV and its wholly-owned Hungarian subsidiary, Vidatech. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates: The preparation of the financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect amounts reported herein. Management believes that such estimates, judgments and assumptions are reasonable and appropriate. However, due to the inherent uncertainty involved, actual results may differ from those based upon management’s judgments, estimates and assumptions. Critical accounting policies requiring the use of estimates are depreciation and amortization and share-based payments Revenue Recognition: Sales are recognized when there is evidence of a sales agreement, the delivery of the goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured, generally upon shipment of product to customers and transfer of title under standard commercial terms. Sales are measured based on the net amount billed to a customer. Generally there are no formal customer acceptance requirements or further obligations. Customers do not have a general right of return on products shipped therefore no provisions are made for return. Accounts Receivable and Allowance for Doubtful Accounts: Accounts receivable are stated at historical value, which approximates fair value. The Company does not require collateral for accounts receivable. Accounts receivable are reduced by an allowance for amounts that may be uncollectible in the future. This estimated allowance is determined by considering factors such as length of time accounts are past due, historical experience of write offs, and customers’ financial condition. Inventories: Inventories are stated at the lower of cost, determined based on weighted average cost or market. Inventories are reduced by an allowance for excess and obsolete inventories based on management’s review of on-hand inventories compared to historical and estimated future sales and usage. Fixed assets: Fixed assets are stated at cost or fair value for impaired assets. Depreciation and amortization is computed principally by the straight-line method. Asset amortization charges are recorded for long lived assets. In the related periods, no asset impairment charges were accounted for. Depreciation is recorded commencing the date the assets are placed in service and is calculated using the straight line basis over their estimated useful lives. The estimated useful lives of the various classes of long-lived assets are approximately 3-7 years. Pensions and Other Post-retirement Employee benefits: In Hungary, pensions are guaranteed and paid by the government or by pension funds, therefore no pensions and other post-retirement employee benefit costs or liabilities are to be calculated and accounted by the Company. Product warranty: The Company accrues for warranty obligations for products sold based on management estimates, with support from sales, quality and legal functions, of the amount that eventually will be required to settle such obligations. At September 30, 2015, the Company had no warranty obligations in connection with products sold. Advertising costs: Advertising and sales promotion expenses are expensed as incurred. Research and development and Investment and Advances to Non-Consolidated Entities: In accordance with ASC 730-10-25 “Accounting for Research and Development Costs,” all research and development (“R&D”) costs are expensed when they are incurred, unless they are reimbursed under specific contracts. Assets used in R&D activity, such as machinery, equipment, facilities and patents that have alternative future use either in R&D activities or otherwise are capitalized. In connection with investments and advances in development-stage technology entities in which the company owns or controls less than a 50% voting interest, (see Note 4) where repayment from such entity is based on the results of the research and development having future economic benefit, the investment and advances are accounted for as costs incurred by the Company as research and development in accordance with ASC 730-20-25 “Research and Development Arrangements”. Income taxes: The Company accounts for income taxes in accordance with ASC 740-10-25, “Accounting for Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided against deferred tax assets to the extent that it is more likely than not that the deferred tax assets will not be realized. Comprehensive Income (Loss): ASC 220-10-25, “Accounting for Comprehensive Income,” establishes standards for reporting and disclosure of comprehensive income and its components (including revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The items of other comprehensive income that are typically required to be disclosed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. Accumulated other comprehensive income, at September 30, 2015 is $666,533. Translation of Foreign Currencies: The U.S. dollar is the functional currency for all of the Company’s businesses, except its operations in Hungary. Foreign currency denominated assets and liabilities for this unit is translated into U.S. dollars based on exchange rates prevailing at the end of each period presented, and revenues and expenses are translated at average exchange rates during the period presented. The effects of foreign exchange gains and losses arising from these translations of assets and liabilities are included as a component of equity, under other comprehensive income. Loss per Share: Under ASC 260-10-45, “Earnings Per Share”, basic loss per common share is computed by dividing the loss applicable to common stockholders by the weighted average number of common shares assumed to be outstanding during the period of computation. Diluted loss per common share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Accordingly, the weighted average number of common shares outstanding for the periods ended September 30, 2015 and 2014, respectively, is the same for purposes of computing both basic and diluted net income per share for such years. For the periods ended September 30, 2015 and 2014, all potential shares of common stock were excluded from diluted EPS as their effect would be anti-dilutive. The Company currently has the following convertible securities issued and outstanding: - 1,000,000 Shares of our Series B Preferred Stock used for the Genetic Immunity acquisition, convertible into 40 shares of common stock per each Series B preferred, or a total of 40,000,000 common shares on a fully converted basis, beginning on January 1, 2014. - 1,000,000 Shares of our Series C Preferred Stock convertible into 20 shares of common stock per each Series C preferred, or a total of 20,000,000 common stock on a fully converted basis. - 1,000,000 Shares of our Series D Preferred Stock convertible into 2 shares of common stock per each Series D preferred, or a total of 2,000,000 common stock on a fully converted basis. - 1,045,000 Shares of our Series E Preferred Stock convertible into 10 shares of common stock per each Series E preferred, or a total of 10,450,000 common stock on a fully converted basis. - And we have one Warrant outstanding, convertible into 3,977,386 Shares of our common stock on a fully converted basis. Business Segment: ASC 280-10-45, “Disclosures About Segments of an Enterprise and Related Information,” establishes standards for the way public enterprises report information about operating segments in annual consolidated financial statements and requires reporting of selected information about operating segments in interim financial statements regarding products and services, geographical areas and major customers. The Company has determined that under ASC 280-10-45, there are no operating segments since substantially all business operations, assets and liabilities are in Hungarian geographic segment. Share-Based Payments: In accordance with ASC 718-10 “Share-Based Payment” all forms of share-based payment (“SBP”) awards including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest. As the Company did not issue any employee SBP prior to September 30, 2007, there is no compensation cost recognized in the accompanied consolidated financial statements. The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 505-50, “Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services,” which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. Non-employee stock-based compensation charges are amortized over the vesting period or period of performance of the services. Recent Accounting Pronouncements: On June 13, 2014, the FASB issued ASU 2014-10 ( “Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in ASC Topic 810, Consolidation”) to eliminate the concept of a development stage entity (“DSE”) from U.S. GAAP. This change rescinds certain financial reporting requirements that have historically applied to DSEs and is intended to result in cost-savings for affected entities, such as certain start-up or research and development entities. In addition, ASU 2014-10 introduces new disclosure requirements about the reporting entity’s risks and uncertainties. ASU 2014-101 is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2014 with an option for the early adoption. The Company adopted this standard on January 1 and has removed all references and disclosures related to its development stage. In August 2014, the Financial Accounting Standards Board (‘‘FASB”) issued Accounting Standards Update (“ASU”) 2014- 15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company is currently evaluating the impact that this standard will have on its financial statements. There were various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Other Receivables

Other Receivables	9 Months Ended
	Sep. 30, 2015
Receivables [Abstract]
Other Receivables	NOTE 3 - OTHER RECEIVABLES September 30, 2015 December 31, 2014 Taxes reclaimable $ 8,609 $ 39,570 Advances given 51,832 40,840 Other — 638 Total $ 60,441 $ 81,048 Given advances contain advances to lawyers on the legal case of Genetic Immunity on its legal case in progress. The Company accounted for impairment on advances given in the amount of $141,889 during 2015 and 2014. Also, advances given presents advances on rental of offices amounting to $13,885 (presented among tax reclaimable in prior period amounting to $30,093).

Intangibles And Fixed Assets

Intangibles And Fixed Assets	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Intangibles and Fixed Assets	NOTE 4 - INTANGIBLES AND FIXED ASSETS Intangibles and Net property and equipment consisted of the followings at September 30, 2015 and December 31, 2014: Intangibles Machinery and other equipments Vehicles Total Net property and equipment Gross book value at December 31, 2013 30,612,186 677,434 327,781 1,005,215 Additions - - - - Impairments (29,570,912) - - - Change in FX rates (154,878) (133,832) (55,378) (189,210) at December 31, 2014 886,396 543,602 272,403 816,005 Additions Disposals Change in FX rates (13,117) (36,719) (19,062) (55,781) at September 30, 2015 873,279 506,883 253,341 760,224 Accumulated depreciation and amortization at December 31, 2013 556,805 547,769 268,252 816,021 Additions 49,004 45,806 - 45,806 Disposals - - - - Change in FX rates (34,740) (92,544) (45,321) (137,865) at December 31, 2014 571,069 501,031 222,931 723,962 Additions 26,074 20,679 - 20,679 Disposals Change in FX rates (10,015) (35,062) (15,600) (50,662) at September 30, 2015 587,128 486,648 207,331 693,979 Net book values at December 31, 2013 30,055,381 129,665 59,529 189,194 December 31, 2014 315,327 42,571 49,472 92,043 September 30, 2015 286,151 20,235 46,010 66,245 The net book value of fixed assets under capital lease amount to $46,010 and $49,472 at September 30, 2015 and at December 31, 2014, respectively. The Patent intangible was acquired with the acquisition of Genetic Immunity in October, 2012. The patents are associated with Dermavir, the company’s drug candidate for a therapeutic HIV viaccine. While the company continues to believe that the value of the patents associated with DermaVir will be recoverable through the eventual marketing and sale of DermaVir, it was determined that due to the continued limited success in raise the necessary amount of capital to bring DermaVir or any other product to market, the Company’s previous cash flow projections, as well as the discount rate used in the estimate of fair value, needed to be revised to reflect the uncertainty as to whether the Company will ultimately realize any cash flows from these patents. As a result, the Company recognized an impairment charge of $29,570,912 in 2014 related to our acquired patent intangibles.

Note Payable

Note Payable	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Note Payable	NOTE 5 - NOTE PAYABLE Mary Passalaqua On April 10, 2007, in connection with reverse merger (See Note 1), the Company assumed a note payable of $250,000 to a former stockholder, Mary Passalaqua originally with one year maturity at April 5, 2008. The note has been expanded by one year to April 5, 2009 with the same conditions. As such note payable was issued immediately prior to the reverse merger, such issuance was recorded as additional compensation by the Company prior to the reverse merger. The note has been partially satisfied through a combination of cash and stock and the balance as of September 30, 2015 is $105,000 plus accrued interest. The note was due on December, 2012. Infinite Funding On July 19, 2011 the Company entered into a Promissory Note with Infinite Funding, Inc whereby Infinite Funding provided $49,000 dollars in loans to the Company. The Note bears interest at 12% per annum. The loan was due on December 2012. On March 16, 2011 the Company entered into a Convertible Promissory Note with Infinite Funding LLC whereby Infinite Funding provided $76,000 dollars in loans to the Company. The note bears interest at 10%, is due December 5, 2011, and is convertible into shares of common stock at a conversion price of $0.05. On December 4, 2011 the Company received an extension to this note to December 31, 2012. On September 30, 2012, the loan was converted into 1,900,000 common stocks at a conversion price of $0.04 per share. Other loans On December 31, 2014 the Company entered into a Promissory Note with a private person provided $22,964, in loans to the Company. The note bears interest at 10%, is due in one year. On July 28, 2014, on August 4, 2014, and on 14 August, 2014 the Company entered into three Promissory Notes with a private person provided $24,000, $55,000 and $75,000 dollars, respectively, in loans to the Company. The note bears interest at 10%, is due in one year. All notes are due within one year and have been classified within current liabilities on our balance sheet. While none of the noteholders have demanded payment as of September 30, 2015, such a demand could not currently be met by the company and could force the company to liquidate.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Stockholders' Equity	NOTE 6 - STOCKHOLDERS’ EQUITY On October 2, 2012 the Company acquired Genetic Immunity, Inc., a US corporation domiciled in the state of Delaware. Genetic Immunity is an immunotherapeutic vaccine company whose lead product candidate DermaVir has passed Phase II clinical trials. Through the acquisitions Genetic Immunity became 100% wholly owned subsidiary. The acquisition was completed for 1,000,000 shares of Series B Preferred stock, convertible into 40 million shares of common stock beginning on January 1, 2014. On October 26, 2011 the Company entered into an equity exchange agreement with each of Messrs. Viktor Rozsnyay and Daniel Kun, Jr. Mr. Rozsnyay is President, CEO and Chairman of the Board of Directors of the Company and Mr. Kun is its Vice-President. Each Agreement is identical and provides in summary form as follows: each of Messrs. Rozsnyay and Kun will deliver twelve million (12,000,000) shares of their shares of common stock of the Company to the Company for cancellation immediately. The Exchange Shares so delivered were returned to the treasury of the Company as unauthorized shares of common stock to be available for subsequent issuance. In return for the surrender of the Exchange Shares, the Company issued and deliver two million (2,000,000) restricted shares of a new class of Series A Preferred shares, 1,000,000 shares each to Mr. Rozsnyay and Mr. Kun. Private placements During May 2015, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 70,000 shares of its Series E Preferred Stock to two unaffiliated private investors for aggregate proceeds of $50,000. On November 28, 2014, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 170,000 shares of its Series E Preferred Stock to five unaffiliated private investors for aggregate proceeds of $165,600. In September, 2014, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 300,000 shares of its Series E Preferred Stock to seven unaffiliated private investors for aggregate proceeds of $300,000. On May 28, 2014, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 200,000 shares of its Series E Preferred Stock to two unaffiliated private investors for aggregate proceeds of $100,000. On April 28, 2014, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 100,000 shares of its Series C Preferred Stock to one unaffiliated private investor for aggregate proceeds of $27,949. On April 7, 2014, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 50,000 shares of its Series E Preferred Stock to one unaffiliated private investor for aggregate proceeds of $50,000. On February 19, 2014, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 200,000 shares of its Series E Preferred Stock to two unaffiliated private investors for aggregate proceeds of $200,000. The holders of Series E Preferred Stock are entitled to receive dividends equal to the amount that would be received if each one share of Series E Preferred stock was fully converted into twelve and one half shares of the common stock. Each one share of the Series E Preferred has voting rights equal to five votes of common Stock. Each share of Series E Preferred stock is convertible into 10 shares of common stock. On November 1, 2013, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 1,000,000 shares of its Series D preferred stock to one affiliated private investor, Peter Boros, Director of the company, for aggregate proceeds of $337,653. This amount was previously provided to the company by Mr. Boros as a loan, and on November 1 Mr. Boros elected to convert this loan into aforementioned preferred stock. The Series D preferred stock is convertible into 2,000,000 shares of common stock on a fully converted basis. No special redemption rights. On October 17, 2013, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 250,000 shares of its Series C Preferred Stock to one unaffiliated private investors for aggregate proceeds of $75,000. On September 26, 2013, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 650,000 shares of its Series C Preferred Stock to two unaffiliated private investors for aggregate proceeds of $195,000. On September 25, 2013, pursuant to a private placement under Regulation D of the Securities Act of 1933, as amended, the Company sold a total of 1,000,000 shares of its common stock to one unaffiliated private investors for aggregate proceeds of $80,000. Series C Preferred Stocks can be converted with a completed form of conversion notice into 20 shares of common stock. The holders of Series C Preferred shall be entitled to receive dividends on a fully converted basis. Each one share of Series C Preferred shall be entitled to the dividend granted to each one share of common stock multiplied by twenty. Dividends on Series C Preferred must be delivered and paid to the holders not later than five business days after each specified payment date of the dividend. On May 9, 2013, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 100,000 shares of its common stock at $0.035 per share to an unaffiliated private investor for aggregate proceeds of $3,500. On April 3, 2013, pursuant to a private placement under Regulation S of the Securities Act of 1933, as amended, the Company sold 1,400,000 shares of its common stock at $0.035 per share to an unaffiliated private investor for aggregate proceeds of $49,000. Consulting agreements On March 10, 2015, the Company issued a total of 1,000,000 shares of restricted our common stock to one unaffiliated entity, Berlini Kft in liu of payment of Geentic Immunity’s laboratory facilities. Also on March 10, 2015, the Company issued a total of 200,000 shares of restricted our common stock to the Company’s Transfer Agent, Fidelity Transfer Company, for services rendered. In connection with a stand-by equity agreement entered into in 2008, the company issued warrants that were later sold by the original warrantholder to Bluestar Consulting. Bluestar Consulting now has the right to acquire, on or before October 8, 2013, 3,977,386 shares of common stock at a per share exercise price of $0.10. The terms of the warrants are such that the exercise price was lowered due to a subsequent round of financing, from $0.29 per share to the price the subsequent investors paid, $0.10 per share. This down round protection feature causes the warrant to fail the criteria in ASC 815-40-15-7 (EITF 07-5) which would permit them to be classified as equity. Consequently, the warrants are recorded at fair value and classified as liabilities and marked to fair value each period. The warrant is extended to October 8, 2018. The fair value of the liability using Black-Scholes valuation at September 30, 2015 is $11,932, which is classified at short term liabilities. The fair value of the liability is established as a Level 3 fair value measurement. The following table shows the movement in fair value along with the change of warrant conditions: September 30, 2015 Book value Fair value Financial liabilities Liabilities measured at fair value 11,932 11,932 December 31, 2014 Book value Fair value Financial liabilities Liabilities measured at fair value 63,638 63,638 Fair value of warrant per share September 30, 2015 December 31, 2014 Per share $0.003 $0.016 The inputs used in fair value estimation are: current share price at September 30, 2015: $ 0.035 exercise price $ 0.10 expected time to expiry (years): 3 risk free rate 3.25 (FED prime rate) expected dividend yield: 0 volatility: 50 % The change in the amount of warrant liability is accounted as other expense. Reconciliation of warrant valuation: Balance at December 31, 2014: $ 63,638 Decrease in fair value of share (51,706 ) Balance at September 30, 2015: $ 11,932

Accounts Payable, Accrued And O

Accounts Payable, Accrued And Other Liabilities	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Accounts Payable, Accrued and Other Liabilities	NOTE 7 - ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES September 30, 2015 December 31, 2014 Accounts payable and accrued expenses $ 1,942,685 $ 1,672,947 Interest accruals 3,003,762 2,792,202 Total $ 4,946,447 $ 4,465,149 In 2007, Genetic Immunity conducted a US$2.0 million convertible debenture bridge in anticipation of a reverse merger which was not consummated due to then current economic and market conditions. The debenture was due August 2009. The US$1.1 million in face value of debentures was purchased by a fund operating under the Small Business Investment Company (“SBIC”) which has since been put into receivership with the U.S. Small Business Administration (the “SBA”). The remaining US$900,000 of face value of the debenture is held by individuals. The debenture holders have liens on certain intellectual property of the Company. Because there is significant know how associated with the intellectual property, the involvement of the Company's management team and scientific team is necessary to commercialize the intellectual property. In 2013, the Company accounted for the late payment interest for the Bridge loan (18%) which increased the accrued interest liability significantly, along with the interest expenses.

Grants Received

Grants Received	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Grants Received	NOTE 8 - GRANTS RECEIVED During 2007 and 2008, Genetic Immunity gained several government grants from the Hungarian state in order to finance the research and development projects. The grants are payable in arrears to 4 projects of the Company: DERMAVI_, DVCLIN01, FIBERSC2 and WINGS. The Company accrued for the grants received and it is reversed to the income statement along with the occurrence of the related expenses. Grants are payable in accordance with the milestone, not annually. Audited financial statements had to be disclosed to State Office as settlement of each milestone. Theses audits have been performed by the statutory auditor of the Hungarian Subsidiary. WINGS is an EU FP7 international consortium grant financed by the European Union. DERMAVI_ is successfully closed in 2009. DVCLIN01 supported the Phase II clinical development of DermaVir. This grant was closed at the end of 2013.. FIBERSC2 supports the investigation of DermaVir mechanism of action with novel fiber integrated microscopy. Originally scheduled for completion in February of 2014, this grant has been extended to August of 2014. WINGS supports the development of West Nile Virus vaccine with DermaVir technology. The grant ended in February of 2014, the Company has filed the required closing documents, this grant has been closed, the related liability is released at the official close at year end.

Short Term Loans

Short Term Loans	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Short Term Loans	NOTE 9 - SHORT TERM LOANS September 30, 2015 December 31, 2014 Bridge Loan $ 2,000,000 $ 2,000,000 RIGHT loan 249,646 274,120 Loans from private persons 21,283 — Bryan Sanders loan 30,000 30,000 Total 2,300,929 2,304,120 Bridge Loan On August 29, 2007, the Company entered into a Bridge Loan agreement as a Senior Secured Convertible Debenture for an amount of $2,000,000. The loan providers are the followings: Name Bridge Amount SBIC Investors Trident $1,100,000 Non-SBIC Investors Andy Browder 25,000 Proto Investments 250,000 Ford Sasser 25,000 Danny Vela 25,000 Steve Walton 150,000 Hilton Wilson 25,000 Will Wilson 250,000 Rodman & Renshaw 150,000 $2,000,000 The loan bears an annual interest rate of 12%. According to the loan agreement, the Company settles the loan principal on the earlier of August 29, 2009 or consummation of a qualifying transaction other than reverse merger effected by the Company in completion of or in connection with a Public Offering. In case of late payment, the Company is liable to pay 18% late interest fee. The accumulated interest payable, along with the late payment interest is accrued in accrued expenses (see Note 6). As of the printing of this document, the US$1.1 million in face value of debentures has been put into receivership with the U.S. SBA. The debenture holders have liens on certain intellectual property of the Company. Because there is significant know how associated with the intellectual property, the involvement of the Company's management team and scientific team is necessary to commercialize the intellectual property.

Other Expenses

Other Expenses	9 Months Ended
	Sep. 30, 2015
Other Income and Expenses [Abstract]
Other Expenses	NOTE 10 - OTHER EXPENSES Other expenses include the revaluation of liability for warrants for Bluestar Consulting in the amount of $51,706.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 - SUBSEQUENT EVENTS None.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies	NOTE 12 - CONTINGENCIES The Company’s wholly-owned subsidiary, Genetic Immunity, has initiated a lawsuit against the National Development Agency of Hungary. In 2009, Genetic Immunity successfully applied for and won an 800 million Hungarian forint (approximately $4,000,000) research grant to conduct dust mite allergy vaccine research. Subsequently, the agency refused to sign the grant and denied payment of funds. The company initiated a lawsuit to request that the court reinstate the contract that resulted in a grant award. On February 13, 2013, an appeals court ruled that the court could not reinstate the contract between Genetic Immunity and the National Development Agency as the contract has been validly in existence since its original execution in 2009. As such Genetic Immunity was ordered to pay 52,500,000 HUF (approximately $250,000) in lawsuit costs. However, simultaneously, the judgment stated that the company is entitled to receive the original grant amount, interest payment and/or damages since the original grant contract is valid. On February 18, 2013, the Company filed a new petition to have the courts establish the damages and awards that Genetic Immunity can receive based on the appeals court’s ruling. The Company is currently seeking 4,800,000,000 HUF (approximately $20 million) for damages sustained. On November 18, 2013, the Company has entered into a six month suspension of said lawsuit, as agreed with the government, in hopes of negotiating an out of court settlement. After the lapse of our six month suspension we once again resumed the trial. As ofMay 14, 2015 we are awaiting the next trial date to be set, anticipated to be in September of 2015, following the judiciary recess. We hope that at this new court event a final resolution will be agreed on and this case will be settled by the end of 2015.

General Information (Policies)

General Information (Policies)	9 Months Ended
	Sep. 30, 2015
General Information Policies
Basis of Presentation	Basis of presentation The accompanying consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America for financial information have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading as of and for the period ended September 30, 2015.
Going Concern and Management's Plan	Going Concern and Management’s Plan The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate the continuation of the Company as a going concern and assume realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses from operations since inception. Management anticipates incurring additional losses in 2015. Further, the Company may incur additional losses thereafter, depending on its ability to generate revenues from the licensing or sale of its technologies and products, or to enter into any or a sufficient number of joint ventures. The Company has minimal revenue to date. There is no assurance that the Company can successfully commercialize any of its technologies and products and realize any revenues therefore. The Company’s technologies and products have never been utilized on a large-scale commercial basis and there is no assurance that any of its technologies or products will receive market acceptance. There is no assurance that the Company can continue to identify and acquire new technologies. As of September 30, 2015, the Company had an accumulated deficit of $45,433,292 and negative working capital of $(8,377,424). These circumstances raise substantial doubt about the ability of the company to continue as a going concern. During 2015 the Company raised a total of $50,000 through private placements of preferred stock. During 2014 and 2013 the Company raised a total of $677,949 and $401,500, respectively through private placements of common and preferred stock. These funds were used to finance operations, to reduce Genetic Immunity debt, and to finance Genetic Immunity’s regulatory process towards a marketing approval application. Additional funds used for these tasks, in the amount of $337,657 were previously provided in the prior years by the director, Peter Boros, who elected in November of 2013 to convert said loan into 1,000,000 shares of our Series D Preferred Stock. On December 31, 2014 the Company entered into a Promissory Note with a private person provided $22,964, in loans to the Company. The note bears interest at 10%, is due in one year. On July 28, 2014, on August 4, 2014, and on 14 August, 2014 the Company entered into three Promissory Notes with a private person provided $24,000, $55,000 and $75,000 dollars, respectively, in loans to the Company. The note bears interest at 10%, is due in one year. While the company has had limited success in raising funds to continue operating, it has significant debt and other liabilitiess due with in the next 12 months with no resources available and no specific plans in place to satisfy these liabilities. If the note holders and vendors demand payment when these liabilities come due, we will be unable to meet their demands and will likely be forced to liquidate. These consolidated financial statements do not include any adjustments relating to the recoverability of recorded asset amounts that might be necessary as a result of the above uncertainty.

Summary Of Significant Accoun20

Summary Of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of PDV and its wholly-owned Hungarian subsidiary, Vidatech. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates: The preparation of the financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect amounts reported herein. Management believes that such estimates, judgments and assumptions are reasonable and appropriate. However, due to the inherent uncertainty involved, actual results may differ from those based upon management’s judgments, estimates and assumptions. Critical accounting policies requiring the use of estimates are depreciation and amortization and share-based payments.
Revenue Recognition	Revenue Recognition: Sales are recognized when there is evidence of a sales agreement, the delivery of the goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured, generally upon shipment of product to customers and transfer of title under standard commercial terms. Sales are measured based on the net amount billed to a customer. Generally there are no formal customer acceptance requirements or further obligations. Customers do not have a general right of return on products shipped therefore no provisions are made for return.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts: Accounts receivable are stated at historical value, which approximates fair value. The Company does not require collateral for accounts receivable. Accounts receivable are reduced by an allowance for amounts that may be uncollectible in the future. This estimated allowance is determined by considering factors such as length of time accounts are past due, historical experience of write offs, and customers’ financial condition.
Inventories	Inventories: Inventories are stated at the lower of cost, determined based on weighted average cost or market. Inventories are reduced by an allowance for excess and obsolete inventories based on management’s review of on-hand inventories compared to historical and estimated future sales and usage.
Fixed Assets	Fixed assets: Fixed assets are stated at cost or fair value for impaired assets. Depreciation and amortization is computed principally by the straight-line method. Asset amortization charges are recorded for long lived assets. In the related periods, no asset impairment charges were accounted for. Depreciation is recorded commencing the date the assets are placed in service and is calculated using the straight line basis over their estimated useful lives. The estimated useful lives of the various classes of long-lived assets are approximately 3-7 years.
Pensions and Other Post-retirement Employee Benefits	Pensions and Other Post-retirement Employee benefits: In Hungary, pensions are guaranteed and paid by the government or by pension funds, therefore no pensions and other post-retirement employee benefit costs or liabilities are to be calculated and accounted by the Company.
Product Warranty	Product warranty: The Company accrues for warranty obligations for products sold based on management estimates, with support from sales, quality and legal functions, of the amount that eventually will be required to settle such obligations. At September 30, 2015, the Company had no warranty obligations in connection with products sold.
Advertising Costs	Advertising costs: Advertising and sales promotion expenses are expensed as incurred.
Research and Development and Investment and Advances to Non-Consolidated Entities	Research and development and Investment and Advances to Non-Consolidated Entities: In accordance with ASC 730-10-25 “Accounting for Research and Development Costs,” all research and development (“R&D”) costs are expensed when they are incurred, unless they are reimbursed under specific contracts. Assets used in R&D activity, such as machinery, equipment, facilities and patents that have alternative future use either in R&D activities or otherwise are capitalized. In connection with investments and advances in development-stage technology entities in which the company owns or controls less than a 50% voting interest, (see Note 4) where repayment from such entity is based on the results of the research and development having future economic benefit, the investment and advances are accounted for as costs incurred by the Company as research and development in accordance with ASC 730-20-25 “Research and Development Arrangements”.
Income Taxes	Income taxes: The Company accounts for income taxes in accordance with ASC 740-10-25, “Accounting for Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided against deferred tax assets to the extent that it is more likely than not that the deferred tax assets will not be realized.
Comprehensive Income (Loss)	Comprehensive Income (Loss): ASC 220-10-25, “Accounting for Comprehensive Income,” establishes standards for reporting and disclosure of comprehensive income and its components (including revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The items of other comprehensive income that are typically required to be disclosed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. Accumulated other comprehensive income, at September 30, 2015 is $666,533.
Translation of Foreign Currencies	Translation of Foreign Currencies: The U.S. dollar is the functional currency for all of the Company’s businesses, except its operations in Hungary. Foreign currency denominated assets and liabilities for this unit is translated into U.S. dollars based on exchange rates prevailing at the end of each period presented, and revenues and expenses are translated at average exchange rates during the period presented. The effects of foreign exchange gains and losses arising from these translations of assets and liabilities are included as a component of equity, under other comprehensive income.
Loss Per Share	Loss per Share: Under ASC 260-10-45, “Earnings Per Share”, basic loss per common share is computed by dividing the loss applicable to common stockholders by the weighted average number of common shares assumed to be outstanding during the period of computation. Diluted loss per common share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Accordingly, the weighted average number of common shares outstanding for the periods ended September 30, 2015 and 2014, respectively, is the same for purposes of computing both basic and diluted net income per share for such years. For the periods ended September 30, 2015 and 2014, all potential shares of common stock were excluded from diluted EPS as their effect would be anti-dilutive. The Company currently has the following convertible securities issued and outstanding: - 1,000,000 Shares of our Series B Preferred Stock used for the Genetic Immunity acquisition, convertible into 40 shares of common stock per each Series B preferred, or a total of 40,000,000 common shares on a fully converted basis, beginning on January 1, 2014. - 1,000,000 Shares of our Series C Preferred Stock convertible into 20 shares of common stock per each Series C preferred, or a total of 20,000,000 common stock on a fully converted basis. - 1,000,000 Shares of our Series D Preferred Stock convertible into 2 shares of common stock per each Series D preferred, or a total of 2,000,000 common stock on a fully converted basis. - 1,045,000 Shares of our Series E Preferred Stock convertible into 10 shares of common stock per each Series E preferred, or a total of 10,450,000 common stock on a fully converted basis. - And we have one Warrant outstanding, convertible into 3,977,386 Shares of our common stock on a fully converted basis.
Business Segment	Business Segment: ASC 280-10-45, “Disclosures About Segments of an Enterprise and Related Information,” establishes standards for the way public enterprises report information about operating segments in annual consolidated financial statements and requires reporting of selected information about operating segments in interim financial statements regarding products and services, geographical areas and major customers. The Company has determined that under ASC 280-10-45, there are no operating segments since substantially all business operations, assets and liabilities are in Hungarian geographic segment.
Share-Based Payments	Share-Based Payments: In accordance with ASC 718-10 “Share-Based Payment” all forms of share-based payment (“SBP”) awards including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest. As the Company did not issue any employee SBP prior to September 30, 2007, there is no compensation cost recognized in the accompanied consolidated financial statements. The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 505-50, “Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services,” which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. Non-employee stock-based compensation charges are amortized over the vesting period or period of performance of the services.
Recent Accounting Pronouncements	Recent Accounting Pronouncements: On June 13, 2014, the FASB issued ASU 2014-10 ( “Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in ASC Topic 810, Consolidation”) to eliminate the concept of a development stage entity (“DSE”) from U.S. GAAP. This change rescinds certain financial reporting requirements that have historically applied to DSEs and is intended to result in cost-savings for affected entities, such as certain start-up or research and development entities. In addition, ASU 2014-10 introduces new disclosure requirements about the reporting entity’s risks and uncertainties. ASU 2014-101 is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2014 with an option for the early adoption. The Company adopted this standard on January 1 and has removed all references and disclosures related to its development stage. In August 2014, the Financial Accounting Standards Board (‘‘FASB”) issued Accounting Standards Update (“ASU”) 2014- 15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company is currently evaluating the impact that this standard will have on its financial statements. There were various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Other Receivables (Tables)

Other Receivables (Tables)	9 Months Ended
	Sep. 30, 2015
Receivables [Abstract]
Schedule of Other Receivables	September 30, 2015 December 31, 2014 Taxes reclaimable $ 8,609 $ 39,570 Advances given 51,832 40,840 Other — 638 Total $ 60,441 $ 81,048

Intangibles And Fixed Assets (T

Intangibles And Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Schedule of Intangibles and Fixed Assets	Intangibles and Net property and equipment consisted of the followings at September 30, 2015 and December 31, 2014: Intangibles Machinery and other equipments Vehicles Total Net property and equipment Gross book value at December 31, 2013 30,612,186 677,434 327,781 1,005,215 Additions - - - - Impairments (29,570,912) - - - Change in FX rates (154,878) (133,832) (55,378) (189,210) at December 31, 2014 886,396 543,602 272,403 816,005 Additions Disposals Change in FX rates (13,117) (36,719) (19,062) (55,781) at September 30, 2015 873,279 506,883 253,341 760,224 Accumulated depreciation and amortization at December 31, 2013 556,805 547,769 268,252 816,021 Additions 49,004 45,806 - 45,806 Disposals - - - - Change in FX rates (34,740) (92,544) (45,321) (137,865) at December 31, 2014 571,069 501,031 222,931 723,962 Additions 26,074 20,679 - 20,679 Disposals Change in FX rates (10,015) (35,062) (15,600) (50,662) at September 30, 2015 587,128 486,648 207,331 693,979 Net book values at December 31, 2013 30,055,381 129,665 59,529 189,194 December 31, 2014 315,327 42,571 49,472 92,043 September 30, 2015 286,151 20,235 46,010 66,245

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Liabilities	The following table shows the movement in fair value along with the change of warrant conditions: September 30, 2015 Book value Fair value Financial liabilities Liabilities measured at fair value 11,932 11,932 December 31, 2014 Book value Fair value Financial liabilities Liabilities measured at fair value 63,638 63,638 Fair value of warrant per share September 30, 2015 December 31, 2014 Per share $0.003 $0.016
Schedule of Inputs Used in Fair Value Estimation	The inputs used in fair value estimation are: current share price at September 30, 2015: $ 0.035 exercise price $ 0.10 expected time to expiry (years): 3 risk free rate 3.25 (FED prime rate) expected dividend yield: 0 volatility: 50 %
Schedule of Reconciliation of Warrant Valuation	Reconciliation of warrant valuation: Balance at December 31, 2014: $ 63,638 Decrease in fair value of share (51,706 ) Balance at September 30, 2015: $ 11,932

Accounts Payable, Accrued And24

Accounts Payable, Accrued And Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable, Accrued and Other Liabilities	September 30, 2015 December 31, 2014 Accounts payable and accrued expenses $ 1,942,685 $ 1,672,947 Interest accruals 3,003,762 2,792,202 Total $ 4,946,447 $ 4,465,149

Short Term Loans (Tables)

Short Term Loans (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Short Term Loans	September 30, 2015 December 31, 2014 Bridge Loan $ 2,000,000 $ 2,000,000 RIGHT loan 249,646 274,120 Loans from private persons 21,283 — Bryan Sanders loan 30,000 30,000 Total 2,300,929 2,304,120
Schedule of Lenders of Bridge Loan	The loan providers are the followings: Name Bridge Amount SBIC Investors Trident $1,100,000 Non-SBIC Investors Andy Browder 25,000 Proto Investments 250,000 Ford Sasser 25,000 Danny Vela 25,000 Steve Walton 150,000 Hilton Wilson 25,000 Will Wilson 250,000 Rodman & Renshaw 150,000 $2,000,000

Other Receivables (Details)

Other Receivables (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Other Receivables Details
Taxes reclaimable	$ 8,609	$ 39,570
Advances given	$ 51,832	40,840
Other		638
Total	$ 60,441	$ 81,048

Intangibles And Fixed Assets (F

Intangibles And Fixed Assets (Fixed Assets) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Change in FX rates	$ 130,751
Property and equipment net book value	66,245	$ 92,043
Machinery and Other Equipments [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross book value opening balance	$ 543,602	$ 677,434
Additions
Impairments
Disposals
Change in FX rates	$ (36,719)	$ (133,832)
Property and equipment gross book value closing balance	506,883	543,602	$ 677,434
Accumulated depreciation and amortization opening balance	501,031	547,769
Additions	$ 20,679	$ 45,806
Disposals
Change in FX rates	$ (35,062)	$ (92,544)
Accumulated depreciation and amortization closing balance	486,648	501,031	$ 547,769
Property and equipment net book value	20,235	42,571	$ 129,665
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross book value opening balance	$ 272,403	$ 327,781
Additions
Impairments
Disposals
Change in FX rates	$ (19,062)	$ (55,378)
Property and equipment gross book value closing balance	253,341	272,403	$ 327,781
Accumulated depreciation and amortization opening balance	$ 222,931	$ 268,252
Additions
Disposals
Change in FX rates	$ (15,600)	$ (45,321)
Accumulated depreciation and amortization closing balance	207,331	222,931	$ 268,252
Property and equipment net book value	46,010	49,472	$ 59,529
Total Net Property And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross book value opening balance	$ 816,005	$ 1,005,215
Additions
Impairments
Disposals
Change in FX rates	$ (55,781)	$ (189,210)
Property and equipment gross book value closing balance	760,224	816,005	$ 1,005,215
Accumulated depreciation and amortization opening balance	723,962	816,021
Additions	$ 20,679	$ 45,806
Disposals
Change in FX rates	$ (50,662)	$ (137,865)
Accumulated depreciation and amortization closing balance	693,979	723,962	$ 816,021
Property and equipment net book value	$ 66,245	$ 92,043	$ 189,194

Intangibles And Fixed Assets (I

Intangibles And Fixed Assets (Intangibles) (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Intangibles And Fixed Assets Intangibles Details
Gross book value opening balance	$ 886,396	$ 30,612,186	$ 30,612,186
Additions
Disposals
Impairments			$ (29,570,912)
Change in FX rates	$ (13,117)		(154,878)
Gross book value closing balance	873,279		886,396
Accumulated depreciation and amortization opening balance	571,069	$ 556,805	556,805
Additions	$ 26,074		$ 49,004
Disposals
Change in FX rates	$ (10,015)		$ (34,740)
Accumulated depreciation and amortization closing balance	587,128		571,069
Net book value	$ 286,151		$ 315,327

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule Of Fair Value of Liabilities) (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Warrant [Member]
Fair value of warrant per share
Per share	$ 0.003	$ 0.016
Book Value [Member]
Financial liabilities
Liabilities measured at fair value	$ 11,932	$ 63,638
Fair Value [Member]
Financial liabilities
Liabilities measured at fair value	$ 11,932	$ 63,638

Stockholders' Equity (Schedul30

Stockholders' Equity (Schedule Of Inputs Used In Fair Value Estimation) (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2015$ / shares
Fair value estimation
current share price at September 30, 2015:	$ 0.035
exercise price	$ 0.10
expected time to expiry (years):	3 years
expected dividend yield:	0.00%
volatility:	50.00%
FED Prime Rate
Fair value estimation
risk free rate	3.25%

Stockholders' Equity (Schedul31

Stockholders' Equity (Schedule Of Reconciliation Of Warrant Valuation) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance at December 31, 2014:	$ 63,638
Decrease in fair value of share	(51,706)	$ 80,741
Balance at September 30, 2015:	11,932
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance at December 31, 2014:	63,638
Decrease in fair value of share	(51,706)
Balance at September 30, 2015:	$ 11,932

Accounts Payable, Accrued And32

Accounts Payable, Accrued And Other Liabilities (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Accounts Payable Accrued And Other Liabilities Details
Accounts payable and accrued expenses	$ 1,942,685	$ 1,672,947
Interest accruals	3,003,762	2,792,202
Total	$ 4,946,447	$ 4,465,149

Short Term Loans (Schedule Of S

Short Term Loans (Schedule Of Short Term Loan) (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Short-term Debt [Line Items]
Short term loans	$ 2,300,929	$ 2,304,120
Bridge Loan [Member]
Short-term Debt [Line Items]
Short term loans	2,000,000	2,000,000
RIGHT Loan [Member]
Short-term Debt [Line Items]
Short term loans	249,646	$ 274,120
Loans From Private Persons [Member]
Short-term Debt [Line Items]
Short term loans	21,283
Bryan Sanders Loan [Member]
Short-term Debt [Line Items]
Short term loans	$ 30,000	$ 30,000

Short Term Loans (Schedule Of L

Short Term Loans (Schedule Of Lenders Of Bridge Loan) (Details)	Aug. 29, 2007USD ($)
Short-term Debt [Line Items]
Bridge loan amount	$ 2,000,000
SBIC Investors - Trident [Member]
Short-term Debt [Line Items]
Bridge loan amount	1,100,000
Non SBIC Investors - Andy Browder [Member]
Short-term Debt [Line Items]
Bridge loan amount	25,000
Non SBIC Investors - Proto Investments [Member]
Short-term Debt [Line Items]
Bridge loan amount	250,000
Non SBIC Investors - Ford Sasser [Member]
Short-term Debt [Line Items]
Bridge loan amount	25,000
Non SBIC Investors - Danny Vela [Member]
Short-term Debt [Line Items]
Bridge loan amount	25,000
Non SBIC Investors - Steve Walton [Member]
Short-term Debt [Line Items]
Bridge loan amount	150,000
Non SBIC Investors - Hilton Wilson [Member]
Short-term Debt [Line Items]
Bridge loan amount	25,000
Non SBIC Investors - Will Wilson [Member]
Short-term Debt [Line Items]
Bridge loan amount	250,000
Non SBIC Investors - Rodman And Renshaw [Member]
Short-term Debt [Line Items]
Bridge loan amount	$ 150,000

General Information (Narrative)

General Information (Narrative) (Details) - USD ($)	Apr. 10, 2007	Nov. 30, 2013	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Working capital			$ (8,377,424)
Total proceeds from private placement of common and preferred stock				$ 677,949	$ 401,500
Debt maturity term			12 months
Series D Preferred Stock [Member] | Director Peter Boros [Member]
Loan amount converted for shares		$ 337,657
Share issued for debt conversion		1,000,000
Preferred Shares [Member]
Total proceeds from private placement of common and preferred stock			$ 50,000
Share issued for debt conversion
Reverse Merger With Vidatech [Member]
No of shares issued in connection with merger	33,300,000

Summary Of Significant Accoun36

Summary Of Significant Accounting Policies (Narrative) (Details) - shares	Sep. 25, 2013	Sep. 30, 2015	Dec. 31, 2014
Preferred stock shares issued		5,990,000	5,920,000
Series B Preferred Stock [Member]
Preferred stock shares issued		1,000,000
Preferred stock shares outstanding		1,000,000
Preferred stock conversion terms		1,000,000 Shares of our Series B Preferred Stock used for the Genetic Immunity acquisition, convertible into 40 shares of common stock per each Series B preferred, or a total of 40,000,000 common shares on a fully converted basis, beginning on January 1, 2014.
Series C Preferred Stock [Member]
Preferred stock shares issued		1,000,000
Preferred stock shares outstanding		1,000,000
Preferred stock conversion terms	Series C Preferred Stocks can be converted with a completed form of conversion notice into 20 shares of common stock.	1,000,000 Shares of our Series C Preferred Stock convertible into 20 shares of common stock per each Series C preferred, or a total of 20,000,000 common stock on a fully converted basis.
Series D Preferred Stock [Member]
Preferred stock shares issued		1,000,000
Preferred stock shares outstanding		1,000,000
Preferred stock conversion terms		1,000,000 Shares of our Series D Preferred Stock convertible into 2 shares of common stock per each Series D preferred, or a total of 2,000,000 common stock on a fully converted basis.
Series E Preferred Stock [Member]
Preferred stock shares issued		1,045,000
Preferred stock shares outstanding		1,045,000
Preferred stock conversion terms		1,045,000 Shares of our Series E Preferred Stock convertible into 10 shares of common stock per each Series E preferred, or a total of 10,450,000 common stock on a fully converted basis.
Minimum [Member]
Estimated useful lives of the various classes of long-lived assets		3 years
Maximum [Member]
Estimated useful lives of the various classes of long-lived assets		7 years

Other Receivables (Narrative) (

Other Receivables (Narrative) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Impairment of advances	$ 141,889	$ 141,889
Advances given	51,832	40,840
Taxes reclaimable	8,609	39,570
Other Receivables - Advances On Rental [Member]
Advances given	$ 13,885
Taxes reclaimable		$ 30,093

Note Payable (Narrative) (Detai

Note Payable (Narrative) (Details) - USD ($)	Dec. 31, 2014	Aug. 14, 2014	Aug. 04, 2014	Jul. 28, 2014	Sep. 30, 2012	Dec. 04, 2011	Jul. 19, 2011	Mar. 16, 2011	Apr. 10, 2007	Sep. 30, 2015	Sep. 30, 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes											$ 154,000
Notes Payable - Mary Passalaqua [Member]
Debt Instrument [Line Items]
Debt amount									$ 250,000
Debt maturity date									Apr. 5, 2008
Debt maturity date, extended									Apr. 5, 2009
Debt maturity description									The note was due on December, 2012.
Note payable carrying value										$ 105,000
Promissory Note Dated July 19, 2011 - Infinite Funding [Member]
Debt Instrument [Line Items]
Debt maturity description							The loan was due on December 2012.
Debt instrument interest rate							12.00%
Proceeds from issuance of notes							$ 49,000
Convertible Promissory Note Dated March 16, 2011 - Infinite Funding [Member]
Debt Instrument [Line Items]
Debt maturity date						Dec. 31, 2012		Dec. 5, 2011
Debt instrument interest rate								10.00%
Proceeds from issuance of notes								$ 76,000
Conversion price of debt					$ 0.04			$ 0.05
Share issued for debt conversion					1,900,000
Promissory Note Dated December 31, 2014 - Private Person [Member]
Debt Instrument [Line Items]
Debt maturity description	Due in one year.
Debt instrument interest rate	10.00%
Proceeds from issuance of notes	$ 22,964
Promissory Note Dated July 28, 2014 - Private Person [Member]
Debt Instrument [Line Items]
Debt maturity description				Due in one year.
Debt instrument interest rate				10.00%
Proceeds from issuance of notes				$ 24,000
Promissory Note Dated August 04, 2014 - Private Person [Member]
Debt Instrument [Line Items]
Debt maturity description			Due in one year.
Debt instrument interest rate			10.00%
Proceeds from issuance of notes			$ 55,000
Promissory Note Dated August 14, 2014 - Private Person [Member]
Debt Instrument [Line Items]
Debt maturity description		Due in one year.
Debt instrument interest rate		10.00%
Proceeds from issuance of notes		$ 75,000

Stockholder's Equity (Narrative

Stockholder's Equity (Narrative) (Details) - shares	Oct. 02, 2012	Oct. 26, 2011	Sep. 30, 2015	Dec. 31, 2014	Jan. 02, 2014
Preferred stock issued			5,990,000	5,920,000
Common Shares [Member] | Messrs. Viktor Rozsnyay, President, CEO and Chairman [Member]
Common stock returned to treasury		12,000,000
Common Shares [Member] | Mr. Daniel Kun, Vice-President [Member]
Common stock returned to treasury		12,000,000
Series B Preferred Stock [Member]
Preferred stock conversion terms			1,000,000 Shares of our Series B Preferred Stock used for the Genetic Immunity acquisition, convertible into 40 shares of common stock per each Series B preferred, or a total of 40,000,000 common shares on a fully converted basis, beginning on January 1, 2014.
Preferred stock issued			1,000,000
Series A Preferred Stock [Member]
Preferred stock issued		2,000,000
Series A Preferred Stock [Member] | Messrs. Viktor Rozsnyay, President, CEO and Chairman [Member]
Preferred stock issued		1,000,000
Series A Preferred Stock [Member] | Mr. Daniel Kun, Vice-President [Member]
Preferred stock issued		1,000,000
Genetic Immunity [Member] | Common Shares [Member]
Percentage of ownership held by parent					100.00%
Genetic Immunity [Member] | Series B Preferred Stock [Member]
No of shares issued in business acquisition	1,000,000
Preferred stock conversion terms	The acquisition was completed for 1,000,000 shares of Series B Preferred stock, convertible into 40 million shares of common stock beginning on January 1, 2014.

Stockholder's Equity (Private P

Stockholder's Equity (Private Placement) (Narrative) (Details) - USD ($)

Nov. 28, 2014

May. 28, 2014

Apr. 28, 2014

Apr. 07, 2014

Feb. 19, 2014

Nov. 01, 2013

Oct. 17, 2013

Sep. 26, 2013

Sep. 25, 2013

May. 09, 2013

Apr. 03, 2013

May. 31, 2015

Sep. 30, 2014

Sep. 30, 2015

Dec. 31, 2014

Dec. 31, 2013

Subsidiary, Sale of Stock [Line Items]

Proceeds from issuance of stock under private placement

$ 677,949

$ 401,500

Common Shares [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

Series E Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Preferred shares convertible description

1,045,000 Shares of our Series E Preferred Stock convertible into 10 shares of common stock per each Series E preferred, or a total of 10,450,000 common stock on a fully converted basis.

Series C Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Preferred shares dividend terms

The holders of Series C Preferred shall be entitled to receive dividends on a fully converted basis. Each one share of Series C Preferred shall be entitled to the dividend granted to each one share of common stock multiplied by twenty. Dividends on Series C Preferred must be delivered and paid to the holders not later than five business days after each specified payment date of the dividend.

Preferred shares convertible description

Series C Preferred Stocks can be converted with a completed form of conversion notice into 20 shares of common stock.

1,000,000 Shares of our Series C Preferred Stock convertible into 20 shares of common stock per each Series C preferred, or a total of 20,000,000 common stock on a fully converted basis.

Series D Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Preferred shares convertible description

1,000,000 Shares of our Series D Preferred Stock convertible into 2 shares of common stock per each Series D preferred, or a total of 2,000,000 common stock on a fully converted basis.

Private Placement - Two Unaffiliated Private Investors, May, 2015 [Member] | Series E Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

70,000

Proceeds from issuance of stock under private placement

$ 50,000

Private Placement - Five Unaffiliated Private Investors, November 28, 2014 [Member] | Series E Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

170,000

Proceeds from issuance of stock under private placement

$ 165,600

Sale of stock transaction date

Nov. 28, 2014

Private Placement - Seven Unaffiliated Private Investors, September, 2014 [Member] | Series E Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

300,000

Proceeds from issuance of stock under private placement

$ 300,000

Private Placement - Two Unaffiliated Private Investors, May 28, 2014 [Member] | Series E Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

200,000

Proceeds from issuance of stock under private placement

$ 100,000

Sale of stock transaction date

May 28, 2014

Private Placement - One Unaffiliated Private Investor, April 28, 2014 [Member] | Series C Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

100,000

Proceeds from issuance of stock under private placement

$ 27,949

Sale of stock transaction date

Apr. 28, 2014

Private Placement - One Unaffiliated Private Investor, April 7, 2014 [Member] | Series E Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

50,000

Proceeds from issuance of stock under private placement

$ 50,000

Sale of stock transaction date

Apr. 7, 2014

Private Placement - Two Unaffiliated Private Investors, February 19, 2014 [Member] | Series E Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

200,000

Proceeds from issuance of stock under private placement

$ 200,000

Sale of stock transaction date

Feb. 19, 2014

Preferred shares dividend terms

The holders of Series E Preferred Stock are entitled to receive dividends equal to the amount that would be received if each one share of Series E Preferred stock was fully converted into twelve and one half shares of the common stock

Preferred shares voting rights

Each one share of the Series E Preferred has voting rights equal to five votes of common Stock

Preferred shares convertible description

Each share of Series E Preferred stock is convertible into 10 shares of common stock.

Private Placement - One Unaffiliated Private Investor, November 1, 2013 [Member] | Series D Preferred Stock [Member] | Peter Boros, Director [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

1,000,000

Proceeds from issuance of stock under private placement

$ 337,653

Sale of stock transaction date

Nov. 1, 2013

Preferred shares convertible description

The Series D preferred stock is convertible into 2,000,000 shares of common stock on a fully converted basis.

Private Placement - One Unaffiliated Private Investor, October 17, 2013 [Member] | Series C Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

250,000

Proceeds from issuance of stock under private placement

$ 75,000

Sale of stock transaction date

Oct. 17, 2013

Private Placement - Two Unaffiliated Private Investors, September 26, 2013 [Member] | Series C Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

650,000

Proceeds from issuance of stock under private placement

$ 195,000

Sale of stock transaction date

Sep. 26, 2013

Private Placement - One Unaffiliated Private Investors, September 25, 2013 [Member] | Common Shares [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

1,000,000

Proceeds from issuance of stock under private placement

$ 80,000

Sale of stock transaction date

Sep. 25, 2013

Private Placement - Unaffiliated Private Investor, May 9, 2013 [Member] | Common Shares [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

100,000

Proceeds from issuance of stock under private placement

$ 3,500

Sale of stock transaction date

May 9, 2013

Share issue price

$ 0.035

Private Placement - Unaffiliated Private Investor, April 3, 2013 [Member] | Common Shares [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued for private placement

1,400,000

Proceeds from issuance of stock under private placement

$ 49,000

Sale of stock transaction date

Apr. 3, 2013

Share issue price

$ 0.035

Stockholder's Equity (Consultin

Stockholder's Equity (Consulting Agreements) (Narrative) (Details) - shares	Mar. 10, 2015	Sep. 30, 2015	Dec. 31, 2008
Common Shares [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Common stock shares issued for services		1,000,000
One Unaffiliated Entity, Berlini Kft [Member] | Common Shares [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Common stock shares issued for services	1,000,000
Company's Transfer Agent- Fidelity Transfer Company [Member] | Restricted Common Stock [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Common stock shares issued for services	200,000
Bluestar Consulting [Member] | Warrant [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Warrants transfered description			Bluestar Consulting now has the right to acquire, on or before October 8, 2013, 3,977,386 shares of common stock at a per share exercise price of $0.10. The terms of the warrants are such that the exercise price was lowered due to a subsequent round of financing, from $0.29 per share to the price the subsequent investors paid, $0.10 per share.

Accounts Payable, Accrued And42

Accounts Payable, Accrued And Other Liabilities (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Aug. 29, 2007
Short-term Debt [Line Items]
Remaining face value of debenture		$ 2,000,000
Non SBIC Investors [Member]
Short-term Debt [Line Items]
Remaining face value of debenture		$ 900,000
Bridge Loan [Member]
Short-term Debt [Line Items]
Late payment interest terms	The Company accounted for the late payment interest for the Bridge loan (18%) which increased the accrued interest liability significantly, along with the interest expenses.

Short Term Loans (Narrative) (D

Short Term Loans (Narrative) (Details) - Bridge Loan [Member]	Aug. 27, 2007
Short-term Debt [Line Items]
Interest rate on loan	12.00%
Debt repayment terms	According to the loan agreement, the Company settles the loan principal on the earlier of August 29, 2009 or consummation of a qualifying transaction other than reverse merger effected by the Company in completion of or in connection with a Public Offering. In case of late payment, the Company is liable to pay 18% late interest fee.

Other Expenses (Narrative) (Det

Other Expenses (Narrative) (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Bluestar Consulting [Member] | Other Expenses [Member]
Revaluation of liability for warrants	$ 51,706

Contingencies (Narrative) (Deta

Contingencies (Narrative) (Details) - Lawsuit For Research Grant [Member]	Nov. 18, 2013USD ($)	Nov. 18, 2013HUF	Feb. 13, 2013USD ($)	Feb. 13, 2013HUF	Dec. 31, 2009USD ($)	Dec. 31, 2009HUF
United States of America, Dollars
Litigation awarded amount					$ 4,000,000
Lawsuit cost			$ 250,000
Damages sought	$ 20,000,000
Defendant name					National Development Agency of Hungary	National Development Agency of Hungary
Plaintiff name					Genetic Immunity	Genetic Immunity
Hungary, Forint [Member]
Litigation awarded amount | HUF						HUF 800,000,000
Lawsuit cost | HUF				HUF 52,500,000
Damages sought | HUF		HUF 4,800,000,000